The subcutaneous administration of liraglutide not only improves hyperglycemia and peripheral IR but also reverses insulin signaling impairment in the brain, leading to decreased AD-associated tau hyperphosphorylation [60]. This evidence concerns the gene INS and Alzheimer disease.